Search results for "Metas"

showing 10 items of 1693 documents

Nab-paclitaxel in pretreated metastatic breast cancer: evaluation of activity, safety, and quality of life

2019

Rossella De Luca,1 Giuseppe Profita,2 Giuseppe Cicero1 1Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy; 2Department of Surgical, Oncological and Oral Sciences, Section of Surgical, University of Palermo, Palermo, Italy Objective: Metastatic breast cancer (MBC) is an incurable disease; the treatment of this disease prolongs survival, improving the quality of life (QoL) with a balance between efficacy and toxicity of the treatment. In recent years, treatment with nab-paclitaxel has improved the already known antitumor activity of conventional paclitaxel, in terms of increased efficacy and better tolerability. The aim o…

breast cancer metastasibreast cancer metastasisoverall survivalAbraxane®Ca15.3painchemotherapyOncoTargets and TherapyOriginal ResearchOncoTargets and Therapy
researchProduct

The C-X-C Motif Chemokine Ligand 1 Sustains Breast Cancer Stem Cell Self-Renewal and Promotes Tumor Progression and Immune Escape Programs

2021

Breast cancer (BC) mortality is mainly due to metastatic disease, which is primarily driven by cancer stem cells (CSC). The chemokine C-X-C motif ligand-1 (CXCL1) is involved in BC metastasis, but the question of whether it regulates breast cancer stem cell (BCSC) behavior is yet to be explored. Here, we demonstrate that BCSCs express CXCR2 and produce CXCL1, which stimulates their proliferation and self-renewal, and that CXCL1 blockade inhibits both BCSC proliferation and mammosphere formation efficiency. CXCL1 amplifies its own production and remarkably induces both tumor-promoting and immunosuppressive factors, includingSPP1/OPN,ACKR3/CXCR7,TLR4,TNFSF10/TRAILandCCL18and, to a lesser exte…

breast cancer stem cellsQH301-705.5animal diseasesSettore MED/50 - Scienze Tecniche Mediche ApplicatechemokinesBiologyCXCR4MetastasisCell and Developmental Biologyimmunity geneCancer stem cellmedicinetumor microenvironmentCXC chemokine receptorsBiology (General)immunity genesTriple-negative breast cancerTumor microenvironmentbreast cancer stem cellchemokineCell BiologyBrief Research Reportrespiratory systemmedicine.diseaseCXCL1Tumor progressiontriple-negative breast cancerCancer researchCCL28Settore MED/46 - Scienze Tecniche Di Medicina Di LaboratorioDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer

2020

A 42-year-old woman with right breast cancer cT4dN2M0 HR +, HER2 +, undergoes mastectomy with axillary lymphadenectomy after neoadjuvant chemotherapy. During adjuvant treatment with trastuzumab and hormone therapy, the patient develops multiple symptomatic encephalic metastases. She undergoes panencephalic radiotherapy and begins chemotherapy with capecitabine and lapatinib. After three months of well tolerated therapy, an important volumetric response of encephalic metastases is observed, with regression of neurological symptoms.

breast cancerLapatinibmetastases
researchProduct

Cancer Stem Cells: From Birth to Death

2019

Abstract Conspicuous investigations have proven the role of cancer stem cells (CSCs) in the onset and progression of a plethora of liquid and solid neoplasms. CSCs are endowed with the capability of initiating tumor growth and becoming dormant at distant organ sites just waiting for optimal conditions amenable for metastatic outgrowth. This cancer subpopulation is inherently resistant to anticancer therapeutics, and its targeting could avoid metastatic disease, which is largely incurable, and clinical relapses. CSCs are considered the Achilles heel of cancer. However, many efforts are necessary to identify univocal CSC markers as well as specific CSC biomarkers of therapeutic response. Here…

business.industryCancer stem cellCancer · Metastasis · Cancer stem cells · Drug resistance · Anticancer drugsCancer researchMedicineCancerTumor growthDiseaseDrug resistancebusinessmedicine.diseaseMetastasis
researchProduct

Corresponding doses of mometasone furoate (MF) in once-daily inhaled fixed-dose combination (FDC) of indacaterol/mometasone furoate (IND/MF) and inda…

2021

business.industryImmunologyFixed-dose combinationmedicineImmunology and AllergyIndacaterolMometasone furoateOnce dailyPharmacologybusinessmedicine.drugJournal of Allergy and Clinical Immunology
researchProduct

Solución del caso 3: Melanoma maligno primario de recto

2009

business.industryX ray computedMelanomaMedicineRadiology Nuclear Medicine and imagingbusinessmedicine.diseaseNuclear medicineMetastasisRadiología
researchProduct

Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries

2008

Over the past 10 years the serological analysis of recombinant cDNA expression libraries (SEREX) has proved to be an effective method for the identification of tumour antigens. In the present study, two prostate cancer libraries were constructed and screened using autologous sera. Fifty five genes were isolated, including 46 known genes and 9 previously uncharacterised genes. Among the known genes, a metastasis-associated gene, MTA1, previously identified by differential cDNA hybridisation, was preferentially expressed in a panel of malignant tissues compared with normal tissues, as analysed by reverse transcriptase-polymerase chain reaction (RT-PCR). MTA1 transcripts were observed to be ov…

business.industrycDNA libraryCancerSEREXTumour antigenmedicine.diseaseArticleGeneral Biochemistry Genetics and Molecular BiologyEST and MTA1MetastasisBiomarker (cell)Prostate cancerAntigenComplementary DNAImmunologyCancer researchMedicinebusinessGeneThe Open Biochemistry Journal
researchProduct

Heat Shock Proteins in Renal Cell Carcinomas

2005

Renal cell carcinoma (RCC) represents one of the most common cancer types in the Western World. One third of the RCC patients had metastasis at presentation with a poor 5-year survival. Nephrectomy is the most important treatment modality of this disease, since most of the RCCs are resistant to cytotoxic chemotherapy and radiation therapy. Recent immunotherapeutic approaches have been shown to improve the survival rate of RCC patients. Thus, RCC appears to have an immunogenic basis, and therefore represents an attractive target for immunotherapies. So far, only a few RCC-associated antigens have been characterized. However, with the implementation of ome-based technologies, an increasing nu…

business.industrymedicine.medical_treatmentCancerContext (language use)Immunotherapyurologic and male genital diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsMetastasisAntigenRenal cell carcinomaHeat shock proteinImmunologymedicineCytotoxic T cellbusiness
researchProduct

Targeting Phosphatases and Kinases: How to Checkmate Cancer

2021

Metastatic disease represents the major cause of death in oncologic patients worldwide. Accumulating evidence have highlighted the relevance of a small population of cancer cells, named cancer stem cells (CSCs), in the resistance to therapies, as well as cancer recurrence and metastasis. Standard anti-cancer treatments are not always conclusively curative, posing an urgent need to discover new targets for an effective therapy. Kinases and phosphatases are implicated in many cellular processes, such as proliferation, differentiation and oncogenic transformation. These proteins are crucial regulators of intracellular signaling pathways mediating multiple cellular activities. Therefore, altera…

cancer stem cellkinaseQH301-705.5PopulationPhosphataseDiseaseReviewBiologyMetastasisphosphatasecancer stem cell kinase phosphatase phosphatase and kinase inhibitors targeted therapiesCell and Developmental BiologyCancer stem cellmedicineBiology (General)educationphosphatase and kinase inhibitorseducation.field_of_studyKinaseCancerCell Biologymedicine.diseasetargeted therapiesCancer cellCancer researchDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct

Meeting the Challenge of Targeting Cancer Stem Cells

2019

Notwithstanding cancer patients benefit from a plethora of therapeutic alternatives, drug resistance remains a critical hurdle. Indeed, the high mortality rate is associated with metastatic disease, which is mostly incurable due to the refractoriness of metastatic cells to current treatments. Increasing data demonstrate that tumors contain a small subpopulation of cancer stem cells (CSCs) able to establish primary tumor and metastasis. CSCs are endowed with multiple treatment resistance capabilities comprising a highly efficient DNA damage repair machinery, the activation of survival pathways, enhanced cellular plasticity, immune evasion and the adaptation to a hostile microenvironment. Due…

cancer stem cells0301 basic medicinecancer stem cellPhysiologymedicine.medical_treatmentPopulationReviewMetastasis03 medical and health sciencesepigenetic inhibitor0302 clinical medicineDifferentiation therapyCancer stem cellepigenetic inhibitorsmedicineanti-cancer therapiesmetastasisEpigeneticseducationlcsh:QH301-705.5education.field_of_studybusiness.industryanti-cancer therapieCancerCell BiologyImmunotherapymedicine.diseasePrimary tumor030104 developmental biologylcsh:Biology (General)030220 oncology & carcinogenesisCancer researchimmunotherapybusinessDevelopmental BiologyFrontiers in Cell and Developmental Biology
researchProduct